Table 1.
Baseline characteristics of participants in the cohort (2017–2019).
| Variable | Frequency (%) | N with Data |
|---|---|---|
| Age at enrollment, median (Q1–Q3), years | 9 (5–12) | 111 |
| Sex, n (%) Male | 63 (56.8) | 111 |
| Any PDR, n (%) Yes | 6 (11.8) | 51 |
| Tuberculosis, n (%) Yes | 16 (16.4) | 111 |
| Isoniazid preventive therapy, n (%) Yes | 34 (30.6) | 111 |
| Cotrimozazole preventive therapy, n (%) Yes | 81 (83.5) | 97 |
| Hematocrit, median (Q1–Q3) in % | 37.3 (35.1–40.5) | 84 |
| CD4+ T cell count, median (Q1–Q3) | 330 (178–741) | 59 |
| Aspartate aminotransferase, median (Q1–Q3) units/L | 38 (30–48) | 108 |
| Alanine aminotransferase, median (Q1–Q3), units/L | 27 (20–38) | 106 |
| Total Bilirubin, median (Q1–Q3) mg/dL | 0.8 (0.4–1.1) | 105 |
| Albumin, median (Q1–Q3) g/dL | 3.8 (3.2–4.2) | 104 |
| Blood urea nitrogen, median (Q1–Q3) mg/dL | 18 (12.1–26.5) | 108 |
| Creatinine, median (Q1–Q3) mg/dL | 0.6 (0.4–0.7) | 107 |
| Total cholesterol, median (Q1–Q3) mg/dL | 120 (96–150) | 106 |
| cART Regimen | 111 | |
| Abacavir-based | 37 (33.3) | |
| Zidovudine-based | 15 (13.5) | |
| Tenofovir-based | 59 (53.2) | |
| WHO clinical stage at enrolment | 110 | |
| Stage 1 | 44 (40) | |
| Stage 2 | 23 (20.9) | |
| Stage 3 | 33 (30) | |
| Stage 4 | 10 (9.1) | |
| Low density lipoprotein, median (Q1–Q3) mg/dL | 45 (32–63) | 108 |
| High density lipoprotein, median (Q1–Q3) mg/dL | 47 (38–65) | 105 |
| Triglyceride, median (Q1–Q3) mg/dL | 103 (87–151) | 106 |
| Weight for age Z score, median (Q1–Q3) mg/dL | –1.2 (–2.5–(–0.6)) | 73 |
| Height for age Z score, median (Q1–Q3) mg/dL | –1.4 (–2.5–(–0.6)) | 109 |
| Body mass index Z score, median (Q1–Q3) mg/dL | –1.2 (–2.4–(–0.3)) | 109 |
| Log10 plasma viral load, median (Q1–Q3) copies/mL | 4.2 (3.3–4.9) | 110 |
Q1–Q3—Interquartile range; n—number; PDR—Pretreatment drug resistance.